Get started
Author

Hitomi Jo

Observed names: H. Jo, HITOMI JO, ジョ, ヒトミ
Institution: New Tokyo Hospital
Observed institutions: Juntendo University, National Cancer Centre Japan, New Tokyo Hospital, Juntendo University Urayasu Hospital, Koto Hospital, National Cancer Center Hospital, National Cancer Center Research Institute
ORCID: 0000-0002-7085-0655
Observed ORCID: 0000-0002-7085-0655
OpenAlex ID: A5055207151
Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab
2021 · Hitomi Jo, Tatsuya Yoshida, et al. · Cancer Immunology Immunotherapy · 38
Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer
2021 · Akiko Tateishi, Hidehito Horinouchi, et al. · Respiratory Investigation · 19
PDF
Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients
2022 · Mayu Ohuchi, Shigehiro Yagishita, et al. · Lung Cancer · 17
PDF
Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2021 · Hitomi Jo, Shigehiro Yagishita, et al. · Molecular Cancer Therapeutics · 13
PDF
Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient
2020 · Munehiro Ito, Shintaro Kanda, et al. · Lung Cancer · 10
Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients
2021 · YUKIKO SHIMODA, TATSUYA YOSHIDA, et al. · Anticancer Research · 8
Clinical outcomes of pembrolizumab therapy in advanced‐ NSCLC patients with poor performance status (≥3) and high PD‐L1 expression ( TPS ≥50%): A case series
2020 · Ryoko Inaba‐Higashiyama, Tatsuya Yoshida, et al. · Thoracic Cancer · 8
PDF
Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma
2016 · Ryota Kanemaru, Yoshiteru Morio, et al. · Respiratory Investigation · 7
Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
2023 · Hitomi Jo, Tatsuya Yoshida, et al. · JTO Clinical and Research Reports · 6
PDF
Autoimmune pulmonary alveolar proteinosis with primary lung cancer in a patient of very advanced years
2015 · Shin‐ichiro Iwakami, Mitsuhiro Fujii, et al. · Geriatrics and gerontology international/Geriatrics & gerontology international · 6
Impact of cachexia in advanced NSCLC patients treated with PD-1 inhibitor.
2020 · Hitomi Jo, Hidehito Horinouchi, et al. · Journal of Clinical Oncology · 4
Loxoprofen-induced interstitial pneumonia: a case report
2016 · Motoyasu Kato, Shinichi Sasaki, et al. · Journal of Medical Case Reports · 4
PDF
The characteristics of long-lasting responders to PD-1 inhibitor in advanced non-small cell lung cancer patients
2019 · H. Jo, T. Yoshida, et al. · Annals of Oncology · 3
The inciting factor for bradycardia in COVID-19 patients: a potential harm of steroid treatment
2024 · Misa Ogiwara, Hiroaki Ihara, et al. · Journal of Thoracic Disease · 2
Predicting pulmonary function using deep-learning-generated synthetic data
2026 · Yuki Muto, Hiroaki Ihara, et al. · Pulmonary Function Diagnostics
Supplementary Figure 1 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2023 · Hitomi Jo, Shigehiro Yagishita, et al.
Supplementary Table 2 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2023 · Hitomi Jo, Shigehiro Yagishita, et al.
PDF
Supplementary Table 3 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2023 · Hitomi Jo, Shigehiro Yagishita, et al.
Supplementary Table 4 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2023 · Hitomi Jo, Shigehiro Yagishita, et al.
Supplementary Figure 2 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2023 · Hitomi Jo, Shigehiro Yagishita, et al.
PDF
Supplementary Table 6 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2023 · Hitomi Jo, Shigehiro Yagishita, et al.
Supplementary Table 1 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2023 · Hitomi Jo, Shigehiro Yagishita, et al.
Supplementary Table 5 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2023 · Hitomi Jo, Shigehiro Yagishita, et al.
Data from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2023 · Hitomi Jo, Shigehiro Yagishita, et al.
Data from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
2023 · Hitomi Jo, Shigehiro Yagishita, et al.
Works count: 31
Citation count: 145
H-index: 7
I10-index: 5
Year
Topic
Type